Apoglyx develops a platform of small molecules modulators of aquaporin function. Its most advanced project targets the aquaglyceroporin channel 9 (AQP9).
The involvement of aquaporin (AQP) channels in the etiology of several diseases has been suggested, and they are targets for a variety of therapeutic approaches.
Aquaporins have been the focus of interest of academic groups led by Prof Per Kjellbom and Prof Søren Nielsen at Lund University (Sweden) and Aarhus University (Denmark), respectively. Associate prof Michael Rützler (Aalborg University) has been instrumental in elucidating AQP9s role in hepatic glucose metabolism and has established a screening platform enabling drug discovery for this target.
Apoglyx utilizes proprietary technology and knowledge based on long-standing research from the researchers in order to discover and develop lead compounds for aquaporins, with the aim to develop therapeutic molecules for type 2 diabetes. A patent application describing a series of highly potent and selective small molecules that function as inhibitors of AQP9 has been submitted in October 2014.